Ambeed.cn

首页 / / / 组蛋白去甲基酶 / Seclidemstat

Seclidemstat {[allProObj[0].p_purity_real_show]}

货号:A486013 同义名: SP-2577;SP-2577 mesylate

Seclidemstat is a potent LSD1 inhibitor, with a mean IC50 of 127 nM.

Seclidemstat 化学结构 CAS号:1423715-37-0
Seclidemstat 化学结构
CAS号:1423715-37-0
Seclidemstat 3D分子结构
CAS号:1423715-37-0
Seclidemstat 化学结构 CAS号:1423715-37-0
Seclidemstat 3D分子结构 CAS号:1423715-37-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Seclidemstat 纯度/质量文件 产品仅供科研

货号:A486013 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 KDM1 KDM2 KDM3 KDM4 KDM5 KDM6 其他靶点 纯度
OG-L002 +++

LSD1, IC50: 20 nM

99%+
ORY-1001 +++

LSD1, IC50: 20 nM

98%
SP-2509 ++++

LSD1, IC50: 13 nM

98+%
GSK2879552 2HCl +

LSD1, Ki: 1.7 μM

99%+
T-3775440 HCl ++++

LSD1, IC50: 2.1 nM

98%
GSK-LSD1 2HCl +++

LSD1, IC50: 16 nM

98%
Pulrodemstat benzenesulfonate 99%+
IOX1 +

KDM2A, IC50: 1.8 μM

+++

KDM3A, IC50: 0.1 μM

++

KDM4E, IC50: 2.3 μM

KDM4C, IC50: 0.6 μM

+

KDM5C, IC50: 19 μM

+

KDM6B, IC50: 1.6 μM

99%
PFI-90 99%+
ML324 +

JMJD2, IC50: 920 nM

99%+
NCGC00244536 ++++

KDM4, IC50: 10 nM

95%
KDM4D-IN-1 ++

KDM4D, IC50: 0.41 μM

99%+
GSK467 ++++

KDM5B, Ki: 10 nM

98%
GSK-J1 +++

JMJD3, IC50: 60 nM

99%+
(Z)-JIB-04 ++

JMJD2A, IC50: 1100 nM

JMJD2E, IC50: 340 nM

++

JARID1A, IC50: 230 nM

++

JMJD3, IC50: 855 nM

97%
CPI-455 ++++

KDM5A, IC50: 10 nM

++++

KDM5, IC50: 10 nM

98%
JIB-04 ++

JMJD2E, IC50: 435 nM

JMJD2D, IC50: 290 nM

++

JARID1A, IC50: 230 nM

++

JMJD3, IC50: 855 nM

98%
GSK-J4 HCl +++

JMJD3, IC50: 60 nM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Seclidemstat 生物活性

描述 Histone methylation plays an important role in the regulation of chromatin structure, and its dynamics regulates important cellular processes. Lysine-specific demethylase 1 (LSD1, also known as KDM1A), the first discovered histone lysine demethylase, is able to demethylase H3K4me1/2 and H3K9me1/2 at target loci in a context-dependent manner. LSD1 regulates the balance between self-renewal and differentiation of stem cells, and is highly expressed in various cancers[1]. Seclidemstat (SP-2577) is a potent and orally bioavailable LSD1 inhibitor, with IC50 of 127 nM[2]. Seclidemstat has been granted Fast Track Designation by the FDA for the treatment of relapsed/refractory patients with Ewing sarcoma and is currently under investigation in an ongoing phase I trial (NCT03600649) in patients with Ewing sarcoma. The starting dose of seclidemstat is 75 mg PO BID with seven dose levels planned by modified Fibonacci schema[3].

Seclidemstat 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03600649 Ewing Sarcoma Phase 1 Recruiting August 2020 United States, California ... 展开 >> Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Leo Mascarhenas, MD          Contact: Magnolia Manzano          United States, Florida Johns Hopkins All Children's Hospital Not yet recruiting Saint Petersburg, Florida, United States, 33701 Contact: Jessica Crimella          Principal Investigator: Jonathan Metts, MD          Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Tiffany Smith, MS, CRC          Principal Investigator: Damon Reed, MD          United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Morgan Krush          Principal Investigator: Steven Dubois, MD          United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Douglas Harrison, MD          Contact: Sherry Melton 收起 <<

Seclidemstat 参考文献

[1]Hosseini A, Minucci S. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics. 2017;9(8):1123-1142.

[2]Hariprasad V, et al. Substituted benzohydrazide analogs as histone demethylase inhibitors. WO 2017004519 A1.

[3]A Phase I dose escalation and expansion study of seclidemstat (SP-2577) a first-in class reversible LSD1 inhibitor for patients with relapsed or refractory Ewing sarcoma.

Seclidemstat 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.09mL

2.22mL

1.11mL

22.18mL

4.44mL

2.22mL

Seclidemstat 技术信息

CAS号1423715-37-0
分子式C20H23ClN4O4S
分子量 450.939
别名 SP-2577;SP-2577 mesylate
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 50 mg/mL(110.88 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。